文献速递肝病消化道肿瘤与早癌

E-twenty-six特异序列变异5(ETV5)通过增强多形核髓源性抑制细胞(PMN-MDSC)介导的免疫抑制促进肝细胞癌进展与转移

E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression.
PubMed 文献 · Gut · 2025-06-06

本研究利用人源化小鼠、原位模型及DEN/CCl4诱导肝癌模型,结合染色质免疫沉淀测序、CUT&Tag和RNA测序,阐明ETV5通过反式激活PD-L1和S100A9募集并增强PMN-MDSC免疫抑制功能,促进肝细胞癌进展与转移;抗S100A9或TLR4/RAGE抑制剂联合抗PD-L1治疗可显著抑制ETV5介导的肝癌进展。

要点

  • ETV5通过反式激活PD-L1和S100A9增强PMN-MDSC的募集与免疫抑制功能。
  • S100A9通过ERK/NF-κB通路在肿瘤微环境中上调ETV5表达,形成正反馈。
  • 抗S100A9或TLR4/RAGE抑制剂联合抗PD-L1可显著抑制ETV5介导的肝癌进展。

核心结论

  • ETV5通过促进PMN-MDSC的募集、浸润和活化,促进肝细胞癌进展与转移。
  • 抗S100A9或TLR4/RAGE抑制剂与抗PD-L1联合应用,有望成为ETV5阳性肝细胞癌的有效联合治疗策略。

研究设计与样本

  • 研究使用人源化小鼠模型、小鼠原位模型及二乙基亚硝胺/四氯化碳(DEN/CCl4)诱导的肝细胞癌模型来检测ETV5的功能。
  • 通过染色质免疫沉淀测序、CUT&Tag和RNA测序筛选ETV5的下游靶点。
  • 使用流式细胞术和免疫荧光检测免疫细胞;使用中和抗体靶向S100钙结合蛋白A9(S100A9)。

主要发现

  • 肝细胞癌细胞中过表达ETV5通过招募PMN-MDSC并增强其免疫抑制能力,促进肝细胞癌转移和免疫逃逸。
  • 机制上,ETV5反式激活程序性死亡配体1(PD-L1)和S100A9的表达。
  • 抑制S100A9或髓系特异性敲除Toll样受体4(TLR4)/晚期糖基化终产物受体(RAGE)可阻碍ETV5诱导的PMN-MDSC募集。
  • 肿瘤微环境中的S100A9通过细胞外信号调节激酶(ERK)/核因子-κB通路升高ETV5表达。
  • ETV5还在MDSC中转录上调PD-L1,从而增强其免疫抑制功能;髓系特异性敲除Etv5可减轻肝细胞癌进展。

关键数值与推荐

  • 开发了单克隆中和S100A9抗体,可有效抑制ETV5介导的PMN-MDSC浸润。
  • 抗S100A9或TLR4/RAGE抑制剂与抗PD-L1治疗协同应用,显著抑制ETV5介导的肝细胞癌进展。

临床怎么用

  • 作者认为,抗S100A9或TLR4/RAGE抑制剂与抗PD-L1联合应用,有望成为ETV5阳性肝细胞癌的有效联合治疗策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the success of immune checkpoint blockade, a lack of understanding of the hepatocellular carcinoma (HCC) immune microenvironment impedes its development. OBJECTIVE: We aim to elucidate the essential function of E-twenty-six-specific sequence variant 5 (ETV5) in regulating the immune microenvironment in HCC. DESIGN: Humanised mouse models, murine orthotopic models and diethylnitrosamine/carbon tetrachloride (DEN/CCl4)-induced HCC models were used to examine the function of ETV5. The downstream targets of ETV5 were screened using chromatin immunoprecipitation sequencing, CUT&Tag and RNA sequencing. Immune cells were examined using flow cytometry and immunofluorescence. S100 calcium-binding protein A9 (S100A9) was targeted by neutralising antibodies. RESULTS: Overexpression of ETV5 in HCC cells facilitated HCC metastasis and immune escape by recruiting and enhancing the immunosuppressive capabilities of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Mechanistically, ETV5 transactivated programmed death ligand 1 (PD-L1) and S100A9 expression. Inhibition of S100A9 or myeloid-specific knockout of toll-like receptor 4 (TLR4)/receptor for advanced glycation endproducts (RAGE), the receptors of S100A9, impeded ETV5-induced PMN-MDSC recruitment. Meanwhile, S100A9 within the tumour microenvironment elevated ETV5 expression via the extracellular signal-regulated kinase (ERK)/nuclear factor-kappa B pathway. Additionally, ETV5 transcriptionally upregulated PD-L1 in MDSCs as well, thereby augmenting their immunosuppressive functions. Myeloid-specific Etv5 knockout attenuated HCC progression. We developed monoclonal neutralising-S100A9 antibodies that effectively inhibited ETV5-mediated PMN-MDSC infiltration. Synergistic application of anti-S100A9 or TLR4/RAGE inhibitors with anti-PD-L1 therapy significantly suppressed ETV5-mediated HCC progression. CONCLUSION: ETV5 facilitates HCC progression and metastasis by promoting the recruitment, infiltration and activation of PMN-MDSCs. Synergistic application of anti-S100A9 or TLR4/RAGE inhibitors with anti-PD-L1 therapy holds great promise as an effective combinational treatment strategy for ETV5-positive HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Zhang Z, Huang W, Hu D, et al. E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression. Gut. 2025. PMID: 40015948. doi:10.1136/gutjnl-2024-333944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。